CTOs on the Move

CanaFarma Corporation

www.canafarmacorp.com

 
Canafarma Corp. has the technology and products that can be offered to the market. Successful experience with chewing gum Yooforic, the flagship product of the company — this confirms! Our product is in demand, so right now we are ready to expand the range, offer new products and enter a new level of development of both production facilities and the distribution network.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Frank Barone
Chief Operating Officer Profile

Similar Companies

Villa Stanley

Villa Stanley is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tactile Systems Technology Inc.

Tactile Systems Technology Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Minneapolis, MN. To find more information about Tactile Systems Technology Inc., please visit www.tactilesystems.com

CleanCare Healthcare Division

CleanCare Healthcare Division is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terra Nova Counseling

Terra Nova Counseling is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.